China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia), marking the debut of China’s first quadrivalent meningococcal conjugate vaccine. The vaccine is now available in Anhui, Shandong, Fujian, Guangxi, Heilongjiang, and Yunnan.
Vaccine Details
Menhycia covalently binds to meningococcal serogroups A, C, W135, and Y using the CRM197 carrier protein. It is approved for use in children as young as three months old, offering broad protection against common pathogenic strains.
Market Context
The quadrivalent polysaccharide conjugate vaccine is included in national immunization programs across 40 countries. However, GSK’s Menveo and Pfizer’s Nimenrix are not marketed in China, leaving a gap that Menhycia aims to fill.
Competitive Landscape
Walvax Bio’s quadrivalent meningococcal conjugate vaccine is currently in Phase III trials in China, positioning Menhycia as the first-to-market product of its kind in the country.-Fineline Info & Tech
